Rockefeller Capital Management
RGLS

Rockefeller Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Rockefeller Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed – – 3491
2022
Q4 		$0 Hold
1
– – ﹤0.01% 4153
2022
Q3 		$0 Hold
1
– – ﹤0.01% 4299
2022
Q2 		$0 Buy
+1
New +$2 ﹤0.01% 4343
2020
Q2 		– Sell
-8,464
Closed -$39K – 2666
2020
Q1 		$39K Sell
8,464
-2,520
-23% -$22K ﹤0.01% 1311
2019
Q4 		$98K Buy
10,984
+10,317
+1,547% +$71.7K ﹤0.01% 978
2019
Q3 		$5K Buy
+667
New +$5.43K ﹤0.01% 1634

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rockefeller Capital Management's RGLS Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Regulus Therapeutics (RGLS) in Q1 2023, closing a stake of 1 share.

Rockefeller Capital Management first reported a position in RGLS in Q3 2019 and held it in 6 quarters. The position peaked at $98K in Q4 2019. 26 funds tracked by Wall St. Rank hold RGLS as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Regulus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 1 Regulus Therapeutics share in Q1 2023.
  • Rockefeller Capital Management first reported a position in Regulus Therapeutics in Q3 2019 and held it in 6 quarters.
  • Rockefeller Capital Management's Regulus Therapeutics position peaked at $98K in Q4 2019.
  • 26 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.